Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iris Ace is a multi-ingredient over-the-counter ophthalmic solution developed by Taisho Pharmaceutical, primarily indicated for the relief of eye fatigue, conjunctival congestion (redness), and blurred vision. The formulation utilizes a combination of active agents to address various symptoms of ocular strain: neostigmine methylsulfate acts as an acetylcholinesterase inhibitor to improve the eye's accommodative focus adjustment; tetrahydrozoline hydrochloride serves as an alpha-adrenergic agonist to constrict blood vessels and reduce redness; and chlorpheniramine maleate provides antihistaminic effects to alleviate itching and irritation. Additionally, the product contains metabolic support components such as taurine, potassium L-aspartate, and pyridoxine hydrochloride (Vitamin B6) to enhance tissue respiration and repair, alongside epsilon-aminocaproic acid which provides anti-inflammatory benefits. It is widely used in Japan to mitigate discomfort caused by prolonged digital screen use and environmental irritants.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Iris Ace.